Last updated on July 2017

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy


Other Details:

For more information, please contact Incyte Corporation at 1.855.463.3463



Find a site near you

Start Over

Research Center

Located in: Gent, Belgium
  Connect »